Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

E-Cadherin Downregulation is Mediated by Promoter Methylation in Canine Prostate Cancer

Full text
Fonseca-Alves, Carlos Eduardo [1, 2] ; Kobayashi, Priscila Emiko [3] ; Leis-Filho, Antonio Fernando [3] ; Lainetti, Patricia de Faria [1] ; Grieco, Valeria [4] ; Kuasne, Hellen [5] ; Rogatto, Silvia Regina [6] ; Laufer-Amorim, Renee [1]
Total Authors: 8
[1] Sao Paulo State Univ, UNESP, Sch Vet Med & Anim Sci, Dept Vet Surg & Anesthesiol, Botucatu, SP - Brazil
[2] Paulista Univ UNIA, Inst Hlth Sci, Bauru, SP - Brazil
[3] Sao Paulo State Univ, UNESP, Dept Vet Clin, Sch Vet Med & Anim Sci, Botucatu, SP - Brazil
[4] Univ Milan, Dept Vet Med, Milan - Italy
[5] AC Camargo Canc Ctr, Int Ctr Res CIPE, Sao Paulo, SP - Brazil
[6] Univ Southern Denmark, Dept Clin Genet, Univ Hosp Southern Denmark, Inst Reg Hlth Res, Vejle - Denmark
Total Affiliations: 6
Document type: Journal article
Source: FRONTIERS IN GENETICS; v. 10, NOV 29 2019.
Web of Science Citations: 0

E-cadherin is a transmembrane glycoprotein responsible for cell-to-cell adhesion, and its loss has been associated with metastasis development. Although E-cadherin downregulation was previously reported in canine prostate cancer (PC), the mechanism involved in this process is unclear. It is well established that dogs, besides humans, spontaneously develop PC with high frequency; therefore, canine PC is an interesting model to study human PC. In human PC, CDH1 methylation has been associated with E-cadherin downregulation. However, no previous studies have described the methylation pattern of CDH1 promoter in canine PC. Herein, we evaluated the E-cadherin protein and gene expression in canine PC compared to normal tissues. DNA methylation pattern was investigated as a regulatory mechanism of CDH1 silencing. Our cohort is composed of 20 normal prostates, 20 proliferative inflammatory atrophy (PIA) lesions, 20 PC, and 11 metastases from 60 dogs. The E-cadherin protein expression was assessed by immunohistochemistry and western blotting and gene expression by qPCR. Bisulfite- pyrosequencing assay was performed to investigate the CDH1 promoter methylation pattern. Membranous E-cadherin expression was observed in all prostatic tissues. A higher number of E-cadherin negative cells was detected more frequently in PC compared to normal and PIA samples. High-grade PC showed a diffuse membranous positive immunostaining. Furthermore, PC patients with a higher number of E-cadherin negative cells presented shorter survival time and higher Gleason scores. Western blotting and qPCR assays confirmed the immunohistochemical results, showing lower E-cadherin protein and gene expression levels in PC compared to normal samples. We identified CDH1 promoter hypermethylation in PIA and PC samples. An in vitro assay with two canine prostate cancer cells (PC1 and PC2 cell lines) was performed to confirm the methylation as a regulatory mechanism of E-cadherin expression. PC1 cell line presented CDH1 hypermethylation and after 5-Aza-dC treatment, a decreased CDH1 methylation and increased gene expression levels were observed. Positive E-cadherin cells were massively found in metastases (mean of 90.6%). In conclusion, low levels of E-cadherin protein, gene downregulation and CDH1 hypermethylation was detected in canine PC. However, in metastatic foci occur E-cadherin re-expression confirming its relevance in these processes. (AU)

FAPESP's process: 12/18426-1 - Epigenetic evaluation of NKX3.1 and CDH1 and immunohistochemistry expression of c-Myc, NKX3.1 and E-cadherin on tissue microarray (TMA) of pre-neoplastic and neoplastic prostate of dogs
Grantee:Carlos Eduardo Fonseca Alves
Support type: Scholarships in Brazil - Doctorate